October 7, 2024 02:44 PM EDTUpdated October 8, 07:45 AM
Pharma
Law

Supreme Court de­clines to re­view patent bat­tle over in­hala­tion pow­der Yutrepia

Katherine Lewin

News Reporter

Liq­uidia’s stock $LQ­DA rose about 10% on Mon­day fol­low­ing a win in the US Supreme Court for its tre­pros­tinil in­hala­tion pow­der Yutrepia.

Liq­uidia has been …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times